Home Blog Page 2050

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss

ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ — CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidelines define diagnostic criteria, treatment goals and treatment approaches, aiming for progress for people living with IgAN and the clinicians who treat them.

The 2025 update defines remission of proteinuria (<0.5 g/day, or ideally at <0.3 g/day) and slowing eGFR decline as key treatment goals. To achieve these goals, the guidelines recommend a treatment approach with therapies simultaneously targeting IgAN-induced nephron loss and IgA-formation.

Within the guidelines it is mentioned that treatment with FILSPARI® (sparsentan), the only Dual Endothelin Angiotensin Receptor Antagonist (DEARA), may be an appropriate first-line approach to manage the responses of IgAN-induced nephron loss in contrast to the RASi-first approach. The guidelines also highlight FILSPARI as the only therapy with proven efficacy compared to optimized RASi in clinical trials — with more patients enrolled in PROTECT than in all prior RASi trials combined.

“The updated KDIGO guidance represents an important step forward for the IgA Nephropathy community,” said Prof. Dr. med. Jürgen Floege, Senior Professor, Div. Nephrology and Clinical Immunology at the University Hospital, RWTH Aachen, Germany. “For patients and clinicians, this provides greater clarity and confidence in navigating treatment decisions, with the ultimate goal of improving long-term kidney outcomes.”

“The new IgA Nephropathy management recommendations provide important guidance for clinicians treating this rare disease. The inclusion of FILSPARI in the KDIGO guidelines is a reflection of its benefit-risk profile and reinforces its role in helping eligible patients reduce proteinuria and slow kidney function loss, while being generally well-tolerated”, said Dr. Achim Obergfell, Global Medical Head Nephrology Portfolio CSL Vifor.  “The updated KDIGO guidelines mark an important milestone for the IgA nephropathy community, reflecting advances in disease understanding, more sophisticated risk assessment and therapies,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. “The placement of FILSPARI underscores the strong clinical evidence supporting its role as a foundational treatment and offers clinicians with clear, evidence-based guidance to improve patient care.”

The now published KDIGO clinical practice guidelines represent a focused update of Chapter 2: IgA Nephropathy/IgA Vasculitis from the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. It sets out to provide a comprehensive and evidence-based framework for healthcare professionals to diagnose, treat, and manage these two types of glomerular diseases. The full guidance was presented at the International Symposium of IgA Nephropathy in September 2025 and will be published as a supplement to the Official Journal of the International Society for Nephrology.

FILSPARI is a non-immunosuppressive therapy for the treatment of IgA Nephropathy approved in the United States (U.S.) and Europe, and in addition to the U.S. has been launched in Germany, Austria, Switzerland, Luxembourg and UK.

About the PROTECT Study

The PROTECT Study is one of the largest interventional studies to date in IgA nephropathy (IgAN) and the only Phase 3 head-to-head trial in this rare kidney disease. It is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400 mg of FILSPARI (sparsentan), compared to 300 mg of irbesartan, in 404 patients ages 18 years and up with IgAN and persistent proteinuria despite receiving at least 50% of max label dose and maximally tolerated ACE or ARB therapy.

The trial met the pre-specified primary endpoint which showed that after 36 weeks patients receiving FILSPARI (n=202) achieved a mean reduction in proteinuria from baseline of 49.8%, compared to a mean reduction in proteinuria from baseline of 15.1% for irbesartan-treated patients (n=202, p<0.0001). In the final analysis conducted after two years, FILSPARI reduced the rate of decline in kidney function from baseline to Week 110 compared to irbesartan. Treatment emergent adverse events were well-balanced between FILSPARI and irbesartan, except for dizziness and hypotension. 

About CSL Vifor

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 29,000+ people and delivers its lifesaving therapies to people in more than 100 countries.

For more information about CSL Vifor, visit CSL.com.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

About IgA Nephropathy

IgA Nephropathy, also called Berger’s disease, is a rare progressive kidney disease characterized by the abnormal buildup of immunoglobulin A (IgA), an antibody that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of the normal filtering mechanisms in the kidney, leading to blood in the urine (hematuria), protein in the urine (proteinuria) and a progressive loss of kidney function. Other symptoms of IgA Nephropathy may include swelling (edema) and high blood pressure.

While rare, IgA Nephropathy is the most common type of primary glomerular disease worldwide and a leading cause of kidney failure. IgA Nephropathy is estimated to affect more than 250,000 people in the licensed territories.

About FILSPARI (sparsentan)

FILSPARI is an innovative, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA) with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R).

FILSPARI was developed by Travere Therapeutics and has been granted Orphan Drug Designation for the treatment of IgA Nephropathy in the UK, Europe and the U.S. FILSPARI is currently available in the U.S. and first markets in Europe. CSL Vifor has been granted exclusive commercialization rights for FILSPARI in Europe, Australia, New Zealand and certain other countries.  For more information, please refer to the Summary of Product Characteristics (SmPC).

CSL Vifor Media Contact

Thomas Hutter

+41 79 957 96 73

media@viforpharma.com 

Travere Therapeutics:

Investors

Media

888-969-7879

888-969-7879  

ir@travere.com

mediarelations@travere.com

 

 

Ask.Legal — Legal AI Built in Hong Kong Without Funding, Revolutionizing Legal Services

HONG KONG, Sept. 26, 2025 /PRNewswire/ — In a legal tech industry dominated by unicorns and billion-dollar ventures, one Hong Kong startup is rewriting the rules. Ask.Legal, developed by DocPro Limited (a Cyberport and HKSTP incubatee), is a secure, cost-effective, and highly accurate AI legal assistant — created entirely without external funding. Much like DeepSeek, Ask.Legal proves that groundbreaking AI can be built with limited staff and resources, yet deliver outstanding results.

The Legal Challenge

SMEs and startups face around legal issues each year, yet only one tenth seek legal advice, deterred by high costs and lack of access. Meanwhile, lawyers and in-house teams often spend hours on research with limited efficiency.

The Ask.Legal Solution

Ask.Legal was built to change this. It is designed for:

  • Lawyers – fast, structured, citation-backed Hong Kong legal analysis
  • SMEs & Startups – quick insights before getting legal advice

With Ask.Legal, users can:

  • Save time – minutes instead of hours for legal research
  • Cut costs – far more affordable than traditional legal analysis
  • Trust results – less than 3% hallucination rate, backed by case law*
  • Maximize efficiency – token-optimized answers reduce costs

Deliver outstanding results

Ask.Legal consistently delivers deeper insights, smarter token usage, and high accuracy. Where others compromise on precision, Ask.Legal sets a new benchmark for the industry.

Proven by Users

Ask.Legal has significantly streamlined our legal analysis workflow. The accuracy and relevance of its responses — especially on Hong Kong law — are a major time-saver for our team.Stephen Yip, Partner at Law Firm

The Founder’s Vision

Founder Kim Chan, a lawyer with over 20 years’ experience at international law firms and investment banks, explained: “Ask.Legal is not about replacing lawyers. It’s about giving them the tools to work smarter, faster, and more cost-effectively — so they can focus on what matters most: delivering real value to their clients.”

The DocPro Ecosystem

Ask.Legal is part of the DocPro ecosystem, which also includes DocLegal.ai, a sister platform providing customizable AI-powered legal documents. Together, they form a cost-efficient, accuracy-driven legaltech suite with over 2,800 legal templates available worldwide.

National Day Celebration – Limited-Time Offer

To celebrate National Day, Ask.Legal is giving away 1,000,000 free tokens (about 100 legal questions) to all new users who sign up before October. This is a unique chance to test Hong Kong’s latest legal AI at no cost.

Sign up now: https://ask.legal

*Based on an internal trial of 200+ Hong Kong legal questions. Results show an 85% reduction in errors compared with other generic AI models tested. Please note the analysis provided does not constitute legal advice.

Media Contact:
DocPro Limited – Ask.Legal / DocLegal.ai
marketing@docpro.com
https://ask.legal | https://doclegal.ai

D-Link Launches New Wi-Fi 7 Dual-Band Routers

Delivering Faster and Reliable Connectivity for the Next Generation of Smart Homes

TAIPEI, Sept. 26, 2025 /PRNewswire/ — D-Link Corporation (TWSE: 2332), one of the global leaders in networking solutions, today announced the launch of its latest Wi-Fi 7 routers: the AQUILA PRO AI M36 BE3600 Wi-Fi 7 Smart Mesh Router and the AQUILA PRO AI R36 BE3600 Wi-Fi 7 Smart Router. As hybrid work, streaming, and smart home adoption accelerate, households and small businesses increasingly require reliable, high-speed connectivity without complexity. In line with its brand promises of MIT quality, creative innovation, solution-oriented, one-stop service, and sustainable design, D-Link introduces these new Wi-Fi 7 solutions to deliver secure, easy-to-manage, and future-ready networks.

D-Link Launches New Wi-Fi 7 Dual-Band Routers, AQUILA PRO AI M36 BE3600 Wi-Fi 7 Smart Mesh Router and the AQUILA PRO AI R36 BE3600 Wi-Fi 7 Smart Router, Delivering Faster and Reliable Connectivity for the Next Generation of Smart Homes
D-Link Launches New Wi-Fi 7 Dual-Band Routers, AQUILA PRO AI M36 BE3600 Wi-Fi 7 Smart Mesh Router and the AQUILA PRO AI R36 BE3600 Wi-Fi 7 Smart Router, Delivering Faster and Reliable Connectivity for the Next Generation of Smart Homes

These cutting-edge routers are powered by the latest Wi-Fi 7 dual-band (2.4 GHz and 5 GHz) technology, featuring Multi-Link Operation (MLO), wider 160 MHz channels, and advanced 4K-QAM modulation to deliver significantly higher speeds, lower latency, and greater efficiency to meet the diverse needs of modern households. Equipped with 2.5G WAN and LAN ports for fast wired connectivity, advanced AI Wi-Fi traffic management for efficient bandwidth allocation and reduced congestion, WPA3 encryption, and parental controls for safer protection. Easily managed through the AQUILA PRO AI app, they offer intuitive setup, monitoring, and customization, setting a new benchmark for Wi-Fi performance in smart homes and SMBs.

Stylish Mesh Wi-Fi for Modern Living- M36 BE3600 Wi-Fi 7 Smart Mesh Router
Engineered for whole-home coverage, the M36 features a mesh network and built-in omnidirectional antennas that deliver 360° spherical coverage, eliminating dead zones. With support for MLO Mesh, it strengthens the connection between routers and devices, delivering smooth connectivity. The M36 also offers the high performance needed for demanding usage scenarios such as 4K streaming and online gaming, while showcasing refined aesthetics inspired by the elegance of an eagle in flight, with a sleek curved form, integrated wing-like antennas, and feather-patterned ventilation.

Engineered for the Next-Gen Smart Home- R36 BE3600 Wi-Fi 7 Smart Router
The R36 is designed to provide powerful performance, featuring four external high-gain antennas for stronger signals, wider coverage, and high-speed connectivity even in environments with multiple obstacles. Optimized for gaming, 4K streaming, and IoT device integration, delivering stable connections for wireless devices throughout the home. The R36 also supports MLO for seamless, low-latency performance that keeps every device running smoothly.

D-Link’s new Wi-Fi 7 routers represent transformative capabilities in wireless networking. The launch of the M36 and R36 highlights D-Link’s commitment to advancing home networking, giving households and small businesses the speed, reliability, and intelligence required to thrive in today’s digital world. With Wi-Fi 7 technology, MLO, 4K-QAM, and 2.5G connectivity. These new routers deliver next-level wireless performance built for the future. With these innovations, D-Link continues to embody its brand spirit of “One Connection • Infinite Possibilities.”

About D-Link
D-Link, a global leader in the networking industry, began expanding worldwide in 1986 and was officially established as D-Link Corporation in 1987. With 90 operational and sales locations across 43 countries, D-Link provides innovative and reliable networking equipment, AI-powered cloud management services, and complete infrastructure solutions for individuals, homes, businesses, and industries. Find out more about D-Link at www.dlink.com.

Uxin Announces Grand Opening of Zhengzhou Used Car Superstore

BEIJING, Sept. 26, 2025 /PRNewswire/ — Uxin Limited (“Uxin” or the “Company”) (Nasdaq: UXIN), China’s leading used car retailer, today announced that its new used car superstore in Zhengzhou, Henan Province will officially open on September 27, 2025.

The Zhengzhou used car superstore has a gross floor area of approximately 150,000 square meters, integrating one of China’s largest used-car showrooms with an in-house reconditioning facility. The site is designed to accommodate up to 5,000 vehicles for display and sale. Following the Company’s successful launch of superstores in Xi’an, Hefei, and Wuhan, Zhengzhou marks Uxin’s fourth superstore, underscoring the Company’s ability to replicate and scale its business model across major Chinese cities.

Zhengzhou is the capital city of Henan Province, which is one of China’s most populous provinces. The city has a resident population exceeding 13 million and over 5 million registered vehicles. Zhengzhou ranks among the top ten cities nationwide in used car transactions and serves as the key transportation hub in central China, providing strong fundamentals to support the operation of a large-scale used car superstore.

With the opening of the Zhengzhou superstore, Uxin is set to deliver a wider selection of high-quality vehicles and professional services to regional consumers, while significantly expanding its market penetration in central China. The continued rollout of new superstores is expected to be a key growth driver of Uxin’s sales volume and financial performance in the coming years.

About Uxin
Uxin is China’s leading used car retailer, pioneering industry transformation with advanced production, new retail experiences, and digital empowerment. We offer high-quality and value-for-money vehicles as well as superior after-sales services through a reliable, one-stop, and hassle-free transaction experience. Under our omni-channel strategy, we are able to leverage our pioneering online platform to serve customers nationwide and establish market leadership in selected regions through offline superstores with inventory capacities ranging from 2,000 to 8,000 vehicles. Leveraging our extensive industry data and continuous technology innovation throughout more than ten years of operation, we have established strong used car management and operation capabilities. We are committed to upholding our customer-centric approach and driving the healthy development of China’s used car industry.

Safe Harbor Statement
This press release contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about Uxin’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk and uncertainties as to the timing of the entry into definitive agreements or consummation of the transactions; the risk that certain closing conditions of the transactions may not be satisfied on a timely basis, or at all; impact of the COVID-19 pandemic; Uxin’s goal and strategies; its expansion plans and successful completion of certain financing transactions; its future business development, financial condition and results of operations; Uxin’s expectations regarding demand for, and market acceptance of, its services; its ability to provide differentiated and superior customer experience, maintain and enhance customer trust in its platform, and assess and mitigate various risks, including credit; its expectations regarding maintaining and expanding its relationships with business partners, including financing partners; trends and competition in China’s used car e-commerce industry; the laws and regulations relating to Uxin’s industry; the general economic and business conditions; and assumptions underlying or related to any of the foregoing.

For investor and media enquiries, please contact:
Uxin Limited Investor Relations
Uxin Limited
Email: ir@xin.com 

The Blueshirt Group
Mr. Jack Wang
Phone: +86 166-0115-0429
Email: Jack@blueshirtgroup.co 

UnionPay Expands Acceptance Across Europe, Now Accepted in Over 90% of European Countries and Regions

MADRID, Sept. 26, 2025 /PRNewswire/ — UnionPay International (“UPI”) announced today significant progress in building a seamless payment environment across Europe, which has now made its services available in over 90% of European countries and region, providing both local residents and international travelers with secure and convenient payment options.

UnionPay’s European footprint covers core payment scenarios: over 80% of merchants accept its cards at POS terminals, and more than six million merchants support UnionPay QuickPass contactless payments, spanning open-loop public transportation, dining, hotels, supermarkets, and tourist attraction ticketing. Since 2025, QuickPass transactions have more than doubled in multiple European markets, reflecting growing adoption among users and merchants.

Major retail and hospitality players have integrated UnionPay into their services. European airport duty-free stores, France’s Galeries Lafayette, the UK’s Harrods, Spain’s El Corte Inglés, and nine Value Retail premium outlets all accept UnionPay cards and most of them also accept UnionPay mobile payments. Dining options—from fine restaurants to fast-food chains and coffee shops—also support the brand, while global hotel groups including Four Seasons, Shangri-La, and Park Hyatt offer UnionPay payments at key European properties. Through partnership with Dojo, UnionPay cardholders can make payments over 110,000 UK merchants, primarily in the hospitality sector.

In travel and tourism, UnionPay has become a staple: it is integrated into urban and intercity transport systems as well as car rental services in Germany, Spain, and Italy. Popular attractions like the London Eye, Disneyland Paris, and Barcelona’s Sagrada Família also allow visitors to purchase tickets online with UnionPay cards. Around 40,000 Selecta vending machines across Europe have enabled UnionPay acceptance.

UnionPay’s local issuance in Europe further deepens its presence: over one million cards have been issued across 13 countries including Serbia, Italy, and Spain. Residents in Spain, France, Germany, and other EEA markets can apply for PecunPay UnionPay cards via the “Yi An” app—usable across UnionPay’s European network and 183 countries and regions worldwide, and compatible with Weixin Pay (also known as WeChat Pay internationally) and Alipay for QR code transactions, facilitating convenient payments for European travelers to China.

With China emerging as a top destination for European tourists (fueled by more visa-free agreements and direct flights), UPI’s “Project Excellence” is enhancing inbound payment convenience. UnionPay’s widespread acceptance in China, plus tax refund services direct to UnionPay cards in gateway cities like Beijing, Guangzhou, Chengdu, and Nanjing, ensure smooth payment experiences for European visitors.

This robust infrastructure benefits both sides: it serves European residents’ daily and travel needs while drawing global UnionPay cardholders—including a fast-growing number of Chinese tourists—to European merchants. UnionPay continues to roll out exclusive offers with local merchants and Chinese issuers to boost spending.

Beyond Europe, hundreds of millions of UnionPay cards have been issued in 83 countries and regions, strengthening cross-border travel and commerce worldwide.

Get Race-Ready for KLSCM 2025 with Pantai Hospital Kuala Lumpur

A Hospital That Runs With You

KUALA LUMPUR, Malaysia, Sept. 26, 2025 /PRNewswire/ — As the countdown begins to the Kuala Lumpur Standard Chartered Marathon (KLSCM) 2025, thousands of runners are training hard to hit their personal bests. But while most are focused on mileage, timing, and gear, Pantai Hospital Kuala Lumpur (PHKL) reminds us that true race-readiness starts from within.

Pantai Hospital Kuala Lumpur at KLSCM 2024
Pantai Hospital Kuala Lumpur at KLSCM 2024

As a trusted healthcare institution for over 50 years, PHKL is not just treating illnesses, it’s actively running with the community, through initiatives that prioritise prevention, sustainability, and holistic wellness. But what makes its involvement in KLSCM particularly meaningful is how it mirrors the hospital’s core mission, bringing healthcare out of the hospital and into the community.

This year, as a Category Sponsor of the Pantai KL 10KM and official medical provider for KLSCM, the hospital reinforces its role as a partner in every step of your health journey. “Medic-On-The-Run” initiative was launched in 2024, which sees medical personnel running in both the half and full marathons, equipped with AEDs and first aid kits to provide on-the-ground medical support instantly. A first in Malaysia, the initiative reflects PHKL’s innovative approach to community healthcare, and its commitment to keeping participants safe, even while they race.

Specialist Tips to Help You Run Smart

At PHKL, preparation for race day goes beyond miles and minutes—it’s about knowing your body, managing risks, and taking proactive steps to stay strong and safe. As you gear up for KLSCM 2025, here’s advice from our trusted specialists:

Specialist Tip: Know Your Heart Before You Run

Dr. Faizal Khan, Consultant Cardiologist, advises all runners—especially those over 35 or with health risk factors—to undergo a structured cardiac evaluation.

“Endurance running is an excellent way to strengthen the cardiovascular system, but it also places unique stress on the heart. A structured cardiac evaluation before participating in a marathon can detect underlying conditions that may not show symptoms in daily life. It’s not just precautionary—it’s essential for safe performance and long-term heart health,” he says.

This type of screening can detect underlying heart issues before they become life-threatening during a race.

Specialist Tip: Don’t Ignore the Warning Signs

Dr. Jeewadas Baladas, Consultant Emergency Medicine Physician, warns that marathon running in Malaysia’s hot and humid conditions can lead to heatstroke — one of the most severe medical emergencies during race day.

“No finish time is worth your health. If you feel unwell—especially confusion, dizziness, nausea and a lack of sweating despite a high body tempreature—stop and seek help immediately,” he says.

Runners are strongly advised to pace themselves, hydrate consistently, and listen to their bodies. PHKL’s race medical teams are trained to respond swiftly to emergencies. “Hydrate wisely, don’t push through warning signs, and remember—finishing safely is the real win.”

Specialist Tip: Don’t Run Through the Pain

Dr. Rizal Abdul Rani, Consultant Orthopaedic Surgeon, emphasises that marathon running places significant stress on the joints and muscles — especially the knees.

“Train gradually, wear the right footwear, and never ignore persistent pain,” he advises. “Running through injury doesn’t make you stronger—it risks long-term damage that could take you off the track for good.”

A proper warm-up, strength conditioning, and listening to your body are key to staying injury-free and enjoying the sport for years to come.

Why Every Runner Should Know Their Cardiac Health

Long-distance running pushes the body to its limits—and the heart, in particular, deserves attention. To help runners get race-ready and heart strong, PHKL is offering an exclusive KLSCM Health Screening Package, available until 31 October 2025 that includes a stress test with a Cardiologist, resting ECG and a comprehensive lab test (blood and urine).

Additionally, PHKL will be onsite during the Race Pack Collection Day, offering two packages KLSCM Stress Test Package and Health Screening Core Package. Participants who sign up for the Health Screening Core Package on the Race Pack Collection Day will also enjoy a 15% discount and exclusive gifts. This is part of PHKL’s commitment to sustainability and community engagement, bringing accessible, preventive healthcare closer to where people are—in this case, the running community.

Whether you’re chasing a personal best or just running for fun, remember: performance starts from within. With Pantai Hospital Kuala Lumpur’s tailored health screenings and expert support, you can feel confident knowing your body is ready to run—strong, safe, and supported.

About Pantai Hospital Kuala Lumpur

Pantai Hospital Kuala Lumpur (PHKL) has remained the heartbeat of Kuala Lumpur, steadfastly dedicated to delivering exceptional care and accessible cutting-edge technology to patients from all walks of life. Our journey began in 1974, with just 68 beds and a team of 20 medical specialists. Fast forward to the present day, we stand as a healthcare icon, operating 507 beds and home to over 200 consultants, each specialising in diverse medical and surgical disciplines.

At Pantai Hospital Kuala Lumpur, we are unwavering in our commitment to provide quality healthcare services while fostering clinical research and trials. We take pride in championing clinical excellence, service quality, and operational efficiency. Our pursuit of excellence has earned us accreditations from the Malaysian Society for Quality in Health (MSQH) and the Joint Commission International (JCI). Additionally, we are honoured to hold certification as a Baby Friendly Hospital and a preferred hospital in Malaysia by the World Health Organization (WHO).

China, Japan target future supply chain cooperation

BEIJING, Sept. 26, 2025 /PRNewswire/ — This is a report from China.org.cn

Ren Hongbin, chairman of the China Council for the Promotion of International Trade (CCPIT), met with a delegation of Japanese business representatives led by Yohei Kono, president of the Japan International Trade Promotion Association, in Beijing on June 3.

The two sides engaged in in-depth discussions on strengthening cooperation in industrial and supply chains, the third China International Supply Chain Expo (CISCE), and the Expo 2025 Osaka.

Ren stated the foundation for cooperation between the economic sectors of China and Japan is solid, with a strong willingness to collaborate. He highlighted the Chinese government’s commitment to developing Sino-Japanese relations and the importance of exchanges between the business communities and the friendship between both peoples.

Kono noted that China has shown strong support for Expo 2025, enabling visitors worldwide to experience its beauty at the China Pavilion. He also expressed confidence that future collaboration between the two organizations will produce even more fruitful results.

China, Japan target future supply chain cooperation

http://www.china.org.cn/2025-06/04/content_118099034.shtml

Moonkie Launches Newborn Gift Set to Simplify Early Parenthood


NEW YORK, US – Media OutReach Newswire – 26 September 2025 – Launching on September 24, 2025, the Moonkie Newborn Gift Set offers a thoughtfully curated 12-piece bundle designed to support new parents through the early months. Priced at $84.99 and available exclusively at Moonkieshop.com, the set includes safe care essentials and meaningful keepsakes—all in one beautifully packaged box.

Created to solve the overwhelm of baby product choices, the set is perfect for both parents and gift-givers looking for something useful, stylish, and heartfelt.

What Parents Will Find in the Gift Set
The unique newborn gift set includes 12 items chosen with new families in mind:

  • Everyday Care: Baby swaddle wrap, goat-hair baby brush, bamboo-bristle massage brush, baby bath brush, and.
  • Soothing and Bonding: Pacifier set, pacifier holder, pacifier clip, and soft baby lovey.
  • Celebrating Milestones: Wooden birth announcement sign, milestone cards, and Montessori puzzle ball.

Parents know these aren’t just “nice to haves”—they’re everyday essentials. From a calming swaddle to a soothing brush and milestone cards, each item helps capture meaningful moments while offering comfort and care.

Designed with Parents in Mind
Moonkie’s approach is shaped by real parenting—long nights, small wins, and the need for practical, comforting products. Inspired by the calm of the moon and the curiosity of a monkey, the brand focuses on essentials parents will truly use—not just more stuff.

When and Where Families Can Get It
The Moonkie Newborn Gift Set launches September 24 exclusively at Moonkieshop.com for $84.99. Perfect for baby showers, milestones, or registries, it combines everyday essentials with keepsakes in one thoughtful bundle. Designed for real life, it takes the guesswork out of gift-giving and supports parents from day one.

Hashtag: #Moonkie




TikTok:https://www.tiktok.com/@moonkie_official
Youtube:https://www.youtube.com/@moonkie_officia

The issuer is solely responsible for the content of this announcement.

About Moonkie

Moonkie is a baby brand built on the balance of calm and play. Inspired by the glow of the moon and the curiosity of a monkey, Moonkie creates products that make everyday parenting easier while celebrating the milestones that matter most. From thoughtfully designed Moonkie baby products that support daily care to keepsakes that capture memories, every item is made with safety, simplicity, and modern design in mind.